BioCryst to Present at the Piper Jaffray Healthcare Conference November 30
November 17 2016 - 7:05AM
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that
executives from BioCryst are scheduled to provide a corporate
update regarding the Company’s clinical programs at the 28th Annual
Piper Jaffray Healthcare Conference in New York on Wednesday,
November 30th at 8:30 a.m. Eastern Time.
Links to a live audio webcast and replay of these
presentations may be accessed on the BioCryst website events page
at http://investor.shareholder.com/biocryst/events.cfm.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals designs, optimizes and
develops novel small molecule drugs that block key enzymes involved
in rare diseases. BioCryst currently has several ongoing
development programs: BCX7353 and second generation oral inhibitors
of plasma kallikrein for hereditary angioedema, and galidesivir,
(formerly BCX4430), a broad spectrum viral RNA polymerase inhibitor
that is a potential treatment for filoviruses. RAPIVAB® (peramivir
injection), a viral neuraminidase inhibitor for the treatment of
influenza, is BioCryst’s first approved product and is currently
marketed in the U.S., Japan, Taiwan and Korea. Post-marketing
commitment development activities are ongoing, as well as
activities to support regulatory approvals in other
territories. For more information, please visit the Company's
website at www.BioCryst.com.
This press release contains forward-looking
statements, including statements regarding future results and
achievements. These statements involve known and unknown risks,
uncertainties and other factors which may cause our actual results,
performance or achievements to be materially different from any
future results, performances or achievements expressed or implied
by the forward-looking statements. Please refer to the documents
BioCryst files periodically with the SEC and located at
http://investor.shareholder.com/biocryst/sec.cfm.
BCRXW
CONTACT: Robert Bennett, BioCryst Pharmaceuticals, +1-919-859-7910
BioCryst Pharmaceuticals (NASDAQ:BCRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
BioCryst Pharmaceuticals (NASDAQ:BCRX)
Historical Stock Chart
From Sep 2023 to Sep 2024